Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
23 Jul 2025 Dapagliflozin Reverses Cardiac Fibrosis in Diabetic HFpEF, Study Finds Dapagliflozin reverses myocardial fibrosis in HFpEF with diabetes, suggesting a disease-modifying effect
The credible explanation for any weight loss from the gelatin trick to lose weight is much simpler: it is a pre-meal protein preload
When you collect a new prescription, note the expiry date and ensure you will use the medication before it expires
SURMOUNT-5 Trial Overview SURMOUNT-5 (NCT05822830) is a multicenter, randomized, open-label Phase 3b trial aimed at assessing the efficacy and safety of Zepbound (tirzepatide) compared to Wegovy (semaglutide) in adults with obesity or overweight, with at least one comorbidity (such as hypertension, dyslipidemia, obstructive sleep apnea (OSA), or cardiovascular disease), and no diabetes
Weight changes can occur during Ozempic treatment, but the Ozempic brand is approved for type 2 diabetes rather than chronic weight management
